Anda di halaman 1dari 1


Pharmaceutical form
Solution for injections.
1 ml of solution contains 25 mg of aminazine (chlorpromazine);
excipients: sodium sulfite anhydrous, sodium metabisulfite, ascorbic acid, sodium chloride,
water for injections
In psychiatric practice: for different types of psychomotor agitation in patients with
schizophrenia, manic agitation associated with manic-depressive psychosis and other mental
diseases (psychopathy; neurotic and reactive states of various origin associated with morbid fear,
anxiety, agitation, insomnia; for psychogenic mood disorders in psychopaths, for psychosis in
mentally retarded patients; for the treatment of alcoholic psychosis and for relief of abstinent
symptoms in alcoholic and inhalant abusers); for potentiating analgesics in chronic pain and
diseases associated with muscular hypertonus (following cerebrovascular accident, stroke).
Aminazine is contraindicated in patients with hepatic impairment (cirrhosis, hepatitis, hemolytic
icterus), renal impairment (nephritis, acute pyelitis, renal amyloidosis, urolithiasis), blood
disorders, progressive encephalopathies and cerebrospinal disorders (slow neuroinfections, e.g.,
disseminated sclerosis), acute exacerbation of gastric and duodenal ulcer, decompensated cardiac
malformations, marked hypotension, thromboembolism, marked myocardial dystrophy,
advanced rheumatic heart disease, multiple bronchiectasis. It is contraindicated in comatose
patients, including those under the influence of barbiturates, alcohol, narcotics. The drug is not
recommended for relief of agitation in acute brain injuries.
Dosage and administration
Aminazine is intended for intramuscular and intravenous injections. Adults are administered 1-5
ml of the drug intramuscularly depending on the patient's condition; for acute psychic agitation
adults are intramuscularly administered 2-3 ml of 2.5% solution in 20 ml of 40% glucose
solution. The maximum doses for adults: intramuscularly a single dose of 150 mg; a daily dose
600 mg; intravenously a single dose of 100 mg; a daily dose 250 mg. The dose for children
is 1-1.5 mg/kg of the bodyweight. In children of 5-12 years of age (with a bodyweight of 23-46
kg) the dose should not exceed 75 mg daily. The medication should be administered 2-3 times
Side effects
Parenteral administration may result in acute hypotension. Nausea, vomiting, jaundice,
photosensitivity may occur.
The use of Aminazine may result in so-called neuroleptic syndrome with the signs of
parkinsonism, acathisia, psychic indifference, reduced alertness and other mental changes.
Occasionally, so-called neuroleptic depression may be observed. Intramuscular administration
may result in injection site induration. Intravenous administration may cause endothelial damage.